Jatt Ii Acquisition CORP

Talawar Therapeutics and JATT II Acquisition Corp. have entered into a definitive business combination agreement to form a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases.

JATT II Acquisition Corp. reports changes in beneficial ownership, with CEO Someit Sidhu's indirect holdings adjusted due to share forfeiture.

JATT Ventures II L.P. reports a forfeiture of 225,000 ordinary shares in JATT II Acquisition Corp. due to over-allotment option expiration.

Talawar Therapeutics is merging with JATT II Acquisition Corp in a SPAC deal, aiming to raise $285 million to advance its eczema asset TALA-125.

JATT II Acquisition Corp and Talawar Tx Inc. have entered into a business combination agreement, with JATT II becoming an indirect wholly-owned subsidiary of Talawar Tx Inc.

Talawar Therapeutics, a biotech company developing bispecific antibodies for I&I diseases, will combine with JATT II Acquisition Corp., a SPAC, to become a publicly listed company, with a $225 million PIPE financing.